.jpg)
- In January 2019, the establishment of Yu-Shen Orbits Technology Company (Stock) was approved by the Taipei City Government.
- In February 2019, a GTP-compliant cell laboratory was completed.
- In December 2019, an application for the review of endometrial stem cell clinical trials was submitted to the Cathay General Hospital.
- In February 2020, an application for the review of CIK non-small cell lung cancer clinical trials was submitted to the Shin Kong Wu Ho-Su Memorial Hospital.
- In January 2022, the Taipei City Government approved the renaming of the company to Zen-Zen Globalwide Biotech Co.,Ltd.
- In January 2023, collaboration with Shin Kong Wu Ho-Su Memorial Hospital commenced for a clinical phase I open- label trial evaluating the safety of using autologous cytokine-induced killer cells (CIK) combined with Navelbine chemotherapy in stage IV non-small cell lung cancer patients.
- In October 2023, collaboration with Buddhist Chengte Hospital began for the "Immunotherapy for Lung Cancer Phase IV" special project.